Shining a Light on the Mechanisms of Drug Resistance to Anti‐PD‐1 Therapy in Non‐small Cell Lung Cancer
Human Mutation · 2026-01 · 2026 (1)
DOI: 10.1155/humu/7216680 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Mutation, online erschienen am 28.10.2026. Verfasst von Hongsheng Guo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology Tianjin Third Central Hospital/Central Hospital Tianjin University Tianjin China tju.edu.cn. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Immune Checkpoint Inhibitors, Lung Neoplasms. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) are first‐line therapies for advanced Nonsmall cell lung cancer (NSCLC), yet managing ICI resistance remains a critical, unavoidable challenge. This study identified genetic markers of anti‐PD‐1 resistance and developed an exploratory predictive model to differentiate responsive and resistant NSCLC patients. The GSE126044 transcriptomic subseries was used as the discovery cohort and included 16 pretreatment NSCLC biopsies (5 responders and 11 nonresponders). The prespecified eight‐gene score was re‐evaluated using repeated stratified out‐of‐fold prediction and was further assessed in two independent checkpoint‐blockade cohorts. The averaged out‐of‐fold AUC in GSE126044 was 0.982 (95% CI 0.931–1.000), although the eight genes had been selected before cross‐validation. External discrimination was limited in GSE135222 (AUC = 0.636, 95% CI 0.363–0.909) and GSE253564 (AUC = 0.567, 95% CI 0.230–0.903). These findings do not support stable generalization of the score across independent treatment settings. The eight‐gene score should be regarded as an exploratory checkpoint‐blockade response‐associated signature. Its potential clinical value requires validation in larger, prospectively collected cohorts with harmonized treatment and response endpoints.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology Tianjin Third Central Hospital/Central Hospital Tianjin University Tianjin China tju.edu.cn.
- Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases Tianjin Institute of Hepatobiliary Disease Tianjin Third Central Hospital/Central Hospital Tianjin University Tianjin China tju.edu.cn.
ORCID-Profile: Hongsheng Guo, Mengmeng Jiang, Hailian Zhang, Jian Zhao, Ying Luo
Zitieren
APA
Guo, H., Jiang, M., Zhang, H., Zhao, J., & Luo, Y. (2026). Shining a Light on the Mechanisms of Drug Resistance to Anti‐PD‐1 Therapy in Non‐small Cell Lung Cancer. Human Mutation, 2026(1). https://doi.org/10.1155/humu/7216680
Vancouver
Guo H, Jiang M, Zhang H, Zhao J, Luo Y. Shining a Light on the Mechanisms of Drug Resistance to Anti‐PD‐1 Therapy in Non‐small Cell Lung Cancer. Human Mutation. 2026;2026(1). doi:10.1155/humu/7216680
BibTeX
@article{Guo2026,
author = {Guo, Hongsheng and Jiang, Mengmeng and Zhang, Hailian and Zhao, Jian and Luo, Ying},
title = {Shining a Light on the Mechanisms of Drug Resistance to Anti‐PD‐1 Therapy in Non‐small Cell Lung Cancer},
journal = {Human Mutation},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/humu/7216680}
}
EUVIMED